Frank Rimerman Advisors LLC Has $879,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Frank Rimerman Advisors LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,397 shares of the company’s stock after purchasing an additional 275 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Zoetis were worth $879,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. State Street Corp grew its holdings in Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after acquiring an additional 95,856 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zoetis by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after acquiring an additional 185,364 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Zoetis by 8.5% during the 4th quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company’s stock worth $906,202,000 after acquiring an additional 433,429 shares during the last quarter. Mizuho Securities USA LLC grew its holdings in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after acquiring an additional 194,542 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $161.33 on Friday. The company has a market capitalization of $72.24 billion, a price-to-earnings ratio of 29.49, a P/E/G ratio of 2.78 and a beta of 0.94. The firm’s 50 day simple moving average is $166.82 and its 200 day simple moving average is $176.15. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.24%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Piper Sandler raised their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Finally, Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.